PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|October 2, 2009
EMEA to fully implement Product Information Management
Author(s)Stephanie Sutton
The EMEA intends to fully implement its Product Information Management (PIM) approach, an initiative designed to improve information management, into the centralized procedure within 2 years, according to a statement of intent from the agency.
Advertisement
The EMEA intends to fully implement its
PIM implementation is in a pilot phase where PIM submissions are only accepted subject to prior discussion with the EMEA. The agency's statement, however, has outlined four main milestones that will lead to full implementation of PIM.
- Q2 2009. The EMEA began migration analysis and planning, with proof-of-concept migration exercises to be conducted towards the end of 2009.
- Q1 2010. All centrally authorized product information will begin to migrate to the PMI format.
- Q3 2010. The formal pilot phase will end. The PIM approach will be strongly recommended for all new marketing authorization applications and post-authorization activities for products that have already migrated.
- End of Q4 2011. All centrally authorized product information should be in PIM format. The EMEA will strongly recommend the PIM approach for all new marketing authorization applications and post authorization activities.
PIM was first introduced by the EMEA in December 2005 to help improve the management and exchange of product information, as well as its quality and consistency. According to a
Ultimately, the agency believes that PIM will lead to better quality information.
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
The EU is focused on strengthening supply-chain resilience, avoiding medicine shortages, simplifying regulations, and implementing new approach methodologies.
Advertisement
Advertisement